Disparities in non-small cell lung cancer (NSCLC) treatment based on race, treatment center
the ONA take:
According to new findings published in the Journal of Thoracic Oncology, researchers have found significant disparities for treatment of African American, Hispanic, and community hospital-treated patients for non-small cell lung cancer (NSCLC).
Specifically, those patient populations were found to be less likely than other patients to receive care for early stage non-small cell lung cancer (NSCLC). For the study, researchers identified nearly 40,000 patients with inoperable stage 1 NSCLC from the National Cancer Database between 2003 and 2011.
They found that African Americans and Hispanics were 40% and 60%, respectively, less likely than others to be treated with either conventional radiation or stereotactic body radiotherapy (SBRT), a technique that delivers higher doses of radiation that requires fewer treatments and is better tolerated.. African Americans and patients without insurance were more likely to receive conventional radiation rather than SBRT if they received radiation at all.
In addition, patients treated in academic hospital were 2.5 times more likely to be treated with SBRT compared with those treated in community hospitals. Patients treated at a high-volume medical center were seven times more likely to receive SBRT compared with those treated at a low-volume center.
Significant disparities for treatment of African American, Hispanic, and community hospital-treated patients for NSCLC.
African Americans, Hispanics, and those who receive care at a community hospital are all significantly less likely than other patients to receive treatment for early stage non-small cell lung cancer, according to a report in the Journal of Thoracic Oncology.
“We found significant disparities for treatment of a curable cancer based on race, insurance status, and whether or not treatment was at an academic or community hospital,” said Dr. Matthew Koshy, a physician in the department of radiation oncology at the University of Illinois at Chicago College of Medicine, and lead author of the study.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|